MARKET

VYGR

VYGR

Voyager Therapeutics Inc
NASDAQ
3.765
-0.475
-11.20%
After Hours: 3.830 +0.065 +1.73% 19:45 05/15 EDT
OPEN
4.240
PREV CLOSE
4.240
HIGH
4.290
LOW
3.760
VOLUME
837.21K
TURNOVER
--
52 WEEK HIGH
5.55
52 WEEK LOW
2.645
MARKET CAP
227.49M
P/E (TTM)
-1.9032
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 2d ago
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Climb Bio (CLYM)
TipRanks · 2d ago
Voyager Therapeutics presents GLP for toxicology data for VY1706
TipRanks · 3d ago
VOYAGER ASGCT LATE BREAKER: SINGLE IV DOSE OF VY1706 WELL TOLERATED, REDUCED TAU IN 3-MONTH GLP TOXICOLOGY DATA; CLINICAL TRIAL IN ALZHEIMER’S DISEASE EXPECTED H2 2026
Reuters · 3d ago
Canaccord Genuity Remains a Buy on Voyager Therapeutics (VYGR)
TipRanks · 5d ago
Weekly Report: what happened at VYGR last week (0504-0508)?
Weekly Report · 5d ago
Voyager Therapeutics Warns of Broad Risk Exposure and Uncertain Outlook in Latest SEC Filings
TipRanks · 05/09 06:01
Analysts Have Conflicting Sentiments on These Healthcare Companies: Voyager Therapeutics (VYGR), Alpha Teknova (TKNO) and RxSight (RXST)
TipRanks · 05/08 18:31
More
About VYGR
Voyager Therapeutics, Inc. is a biotechnology company engaged in leveraging the power of human genetics to modify the course of neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.

Webull offers Voyager Therapeutics Inc stock information, including NASDAQ: VYGR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VYGR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VYGR stock methods without spending real money on the virtual paper trading platform.